CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? Association of Abnormal Left Ventricular Functional Reserve With Outcome in Heart Failure With Preserved Ejection Fraction Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF SPECT and PET in ischemic heart failure Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
|<<... 8 9 10 11 12 13 14 ...>>|

Guideline2018 Oct 31.

JOURNAL：Heart Rhythm. Article Link

2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

Kusumoto FM, Schoenfeld MH, Barrett C et al. Keywords: bradycardia; cardiac conduction delay; guideline; ACC; AHA

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top